IOncology

Editor’s Note: The China National Medical Products Administration (NMPA) has officially approved the novel CDK4/6 inhibitor (CDK4/6i) Lerociclib for two indications in adult patients with hormone receptor–positive, HER2–negative (HR+/HER2-) locally…

Editor’s Note: CDK4/6 inhibitors (CDK4/6i) play a pivotal role in the treatment of HR+/HER2– advanced breast cancer (ABC). However, their efficacy and safety profiles vary across different agents. There remains…

Introduction CDK4/6 inhibitors (CDK4/6i) have become the cornerstone of standard therapy for patients with HR+/HER2- advanced breast cancer. However, differences in efficacy and safety profiles exist among currently approved CDK4/6…

Editor’s Note: On May 29, 2025, China’s National Medical Products Administration (NMPA) simultaneously approved Lerociclib (汝佳宁®, Lerociclib) for two indications in adult patients with hormone receptor–positive (HR+), human epidermal growth…

Editor’s Note: CDK4/6 inhibitors (CDK4/6i) have dramatically improved outcomes for patients with hormone receptor–positive, HER2–negative (HR+/HER2-) advanced breast cancer, yet differences remain among available agents in terms of efficacy, safety,…

Editor’s Note: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have become a key component of treatment for patients with HR+/HER2– advanced breast cancer (ABC), spanning first-line, second-line, and even post-line reuse settings.…

Editor’s Note: Breast cancer remains the most common malignancy among women, with hormone receptor–positive/HER2-negative (HR+/HER2–) cases accounting for approximately 70% of all diagnoses. For patients with advanced disease, first-line therapy…

Editor’s Note: At the 8th Conference on Oncology Precision Medicine and the 11th Conference on Individualized Therapy for Breast Cancer (2025 COMB), Oncology Frontier invited Professor Tao Wang (Fifth Medical…

On August 22–23, 2025, the 13th Ludaopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease Foundation,…